BUSINESS
At Shivalik Rasayan, pharma comes up as a big growth lever
Medicamen Biotech plans to go for domestic launch of oncology formulations from January 2022, in sync with API supply from Shivalik Rasayan. This is the key near-term trigger.
BUSINESS
Supriya Lifescience IPO: A play on lower supply-chain risk for APIs
Supriya Lifescience's key strengths include 12 products, contributing to 67 percent of sales, which are backward integrated to the level of basic chemicals
BUSINESS
Fed presses the pedal harder on taper on stronger growth
Fed chair Jerome Powell indicated that the time between the end of tapering and the first rate hike could be short. Interestingly, the rationale for that has less to do with inflation, but more to do with the strong demand environment and labour market tightness
BUSINESS
Medplus Health Services IPO: What does the investment prescription read?
Investors can wait for traction in operational performance post the listing before taking a call on investment in Medplus Health Services
BUSINESS
Galaxy Surfactants looks forward to life beyond cost inflation
Operationalisation of new plants and the overall capacity utilisation of 67 percent provide enough room to meet medium-term demand for Galaxy Surfactants
BUSINESS
IPCA Labs: Domestic beat offsets API weakness
The key near-term challenge for IPCA is with respect to API sales. The company expects a softer Q3 due to the supply disruption in Sartan APIs and elevated raw material prices
BUSINESS
Explained, the US earnings season
In 2021, earnings have accounted for the lion’s share of S&P 500's total return
BUSINESS
Tarsons Products IPO: A play on rapid growth in health care research
Going forward, research demand in Contract Research Organisations, IVF clinics and diagnostic labs is expected to lead the overall demand for Tarsons Products
BUSINESS
Navin Fluorine: Executing multi-year contract template
Navin Fluorine's recent success on new molecule/product launches stems from its in-house R&D at the Surat facility. This new deal is one of them
BUSINESS
Vidhi Specialty: Is the margin contraction a worry for the long term?
We continue to look at Vidhi as the preferred way to play the food colour theme because of its improved operational metrics
BUSINESS
Fed tapers, but no tantrum
While the “tapering” is steeper than earlier cycle of 2014, Jerome Powell emphasized its need, given that inflation this time is much higher, job openings are better and “demand is very, very strong”.
BUSINESS
Sun Pharma: Fully valued, though performance impressive
Sales of specialty products during the reporting quarter clocked $157 million against $148 million in Q1FY22 and $108 million in Q2FY21.
BUSINESS
Laurus Labs: New growth levers taking shape
The businesses to track for Laurus Labs, as far as future growth trajectory is concerned, are that of synthesis and biotech
BUSINESS
Cadila: Unfolding vaccine opportunity can offset US headwinds
For a longer term play, Cadila has a promising pipeline for NCEs (New chemical entities), biosimilars and injectables
BUSINESS
Dr Reddy’s: Aced by emerging markets' growth
While DRL is hit by pricing erosion in the US business, potential growth in the limited competition products underlines a positive outlook
BUSINESS
Lupin: Competitive pressure remains in the US market
Lupin guided for 16 percent EBITDA margin in H2 of FY22. While sequentially it indicates normalisation, given the elevated pricing pressure in the US market, execution will be closely monitored
BUSINESS
Hikal: 'China plus' opportunity adds to conviction for capex
For FY21 and FY22, Hikal is spending close to Rs 600 crore in capacity enhancement, where the major part of the benefit will accrue in FY24
BUSINESS
SRF: Inflation can impact capex payback period
For FY22, SRF's capex allocation stands at Rs 1,500-1,800 crore. The capex spent so far is nearly Rs 600 crore, which is expected to go up in H2
BUSINESS
Cipla: Focus shifts to FY23 launches
In the US market, while the Albuterol opportunity is stabilising for Cipla, traction for Arformoterol and the high-value product launch calendar in H2 FY23 is a key watch
BUSINESS
Ami Organics: What should investors do, post recent correction?
According to the management of Ami Organics, the priority for the acquired business of Gujarat Organics is to stabilise revenue and focus on reducing inefficiencies
MONEYCONTROL-RESEARCH
Gland Pharma: Operating leverage to offset input cost pain
As far as geographical diversification is concerned, Gland Pharma's foray into non-US markets is expected to accelerate. It's seen to leverage from products already approved in the US for launch in other markets
BUSINESS
Syngene: Look beyond the near-term input cost pressure
Syngene continues to guide for a mid-teen revenue growth in FY22. This appears possible, given the improved demand scenario and the strong traction in H1 FY22
BUSINESS
Navin Fluorine: Should investors accumulate the stock, post recent correction?
Recent initiatives present a significant opportunity as Navin continues to invest in talent and technology and get new inquiries from innovators
BUSINESS
What should investors do with this diagnostic play as COVID cases drop?
Krsnaa Diagnostics presents superior contract execution and scalability in radiology diagnostics
